Notice: This company has been marked as potentially delisted and may not be actively trading. BioTelemetry (BEAT) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BEAT vs. IMAC, SGHT, LUNG, ANIK, UTMD, NVRO, SKIN, OBIO, NPCE, and PROFShould you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include IMAC (IMAC), Sight Sciences (SGHT), Pulmonx (LUNG), Anika Therapeutics (ANIK), Utah Medical Products (UTMD), Nevro (NVRO), Beauty Health (SKIN), Orchestra BioMed (OBIO), NeuroPace (NPCE), and Profound Medical (PROF). These companies are all part of the "medical" sector. BioTelemetry vs. IMAC Sight Sciences Pulmonx Anika Therapeutics Utah Medical Products Nevro Beauty Health Orchestra BioMed NeuroPace Profound Medical IMAC (NASDAQ:IMAC) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has more volatility & risk, IMAC or BEAT? IMAC has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500. Do analysts rate IMAC or BEAT? BioTelemetry has a consensus price target of $8.00, suggesting a potential upside of 221.29%. Given BioTelemetry's higher possible upside, analysts clearly believe BioTelemetry is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABioTelemetry 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IMAC or BEAT? In the previous week, IMAC had 12 more articles in the media than BioTelemetry. MarketBeat recorded 12 mentions for IMAC and 0 mentions for BioTelemetry. IMAC's average media sentiment score of 0.02 beat BioTelemetry's score of 0.00 indicating that IMAC is being referred to more favorably in the media. Company Overall Sentiment IMAC Neutral BioTelemetry Neutral Which has preferable valuation and earnings, IMAC or BEAT? IMAC has higher revenue and earnings than BioTelemetry. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M1.97-$10.54MN/AN/ABioTelemetryN/AN/A-$14.64M-$0.62-4.02 Do institutionals and insiders hold more shares of IMAC or BEAT? 24.3% of IMAC shares are held by institutional investors. Comparatively, 7.8% of BioTelemetry shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 20.9% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is IMAC or BEAT more profitable? BioTelemetry has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat BioTelemetry's return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% BioTelemetry N/A -121.20%-111.73% Does the MarketBeat Community prefer IMAC or BEAT? BioTelemetry received 319 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.31% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote. CompanyUnderperformOutperformIMACOutperform Votes7160.17% Underperform Votes4739.83% BioTelemetryOutperform Votes39063.31% Underperform Votes22636.69% SummaryIMAC beats BioTelemetry on 8 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get BioTelemetry News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAT vs. The Competition Export to ExcelMetricBioTelemetrySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.13M$4.41B$5.40B$8.53BDividend YieldN/A42.37%5.13%4.14%P/E Ratio-4.0238.74115.5615.18Price / SalesN/A65.071,484.3492.77Price / CashN/A49.1039.6634.07Price / Book4.084.264.665.02Net Income-$14.64M$11.52M$119.06M$225.46M BioTelemetry Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEATBioTelemetry2.5627 of 5 stars$2.49+2.9%$8.00+221.3%+94.5%$66.13MN/A-4.021,700Upcoming EarningsShort Interest ↓IMACIMACN/A$1.11-6.7%N/A-30.7%$29.40M$15.22M0.00106SGHTSight Sciences2.1171 of 5 stars$5.21+4.2%$7.25+39.2%+229.7%$262.12M$81.06M-4.87210Upcoming EarningsLUNGPulmonx2.6535 of 5 stars$6.27+0.3%$14.67+133.9%-30.9%$245.47M$68.68M-4.27250Analyst ForecastNews CoverageANIKAnika Therapeutics4.012 of 5 stars$16.53-3.4%$30.50+84.5%-16.0%$244.64M$166.66M-3.26357Analyst ForecastNews CoverageHigh Trading VolumeUTMDUtah Medical Products3.9517 of 5 stars$64.09+1.1%N/A-19.1%$223.03M$50.22M15.01180Analyst UpgradeNews CoverageNVRONevro2.5994 of 5 stars$5.53+0.4%$10.55+90.7%-62.0%$206.18M$426.10M-2.601,215Analyst UpgradeSKINBeauty Health2.9254 of 5 stars$1.66+2.8%$2.46+48.1%-58.1%$205.87M$398M-2.001,030OBIOOrchestra BioMed2.2295 of 5 stars$5.29+2.7%$15.75+197.7%+12.6%$200.12M$2.76M-3.3556Gap DownNPCENeuroPace3.3071 of 5 stars$6.29-2.5%$14.00+122.6%-8.8%$183.67M$65.42M-5.77170Gap UpPROFProfound Medical2.1805 of 5 stars$7.35+1.1%$13.75+87.1%-13.3%$181.25M$7.20M-6.02150Upcoming EarningsNews Coverage Related Companies and Tools Related Companies IMAC Alternatives Sight Sciences Alternatives Pulmonx Alternatives Anika Therapeutics Alternatives Utah Medical Products Alternatives Nevro Alternatives Beauty Health Alternatives Orchestra BioMed Alternatives NeuroPace Alternatives Profound Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BEAT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioTelemetry, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioTelemetry With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
